A promising research work. Hats off to American Diabetes Association & Novo Nordisk . Well they would fund the study. The Association, from its very inception is fighting against this deadly, life-threatening, chronic disorder and has invested more than $500 million to fund different diabetes research projects.
And Nordisk, very excited and enthusiastic about the recent project initiative, has always given high priority to the health and well being of people living in diabetes.
With this huge grant, the researchers will study the effects of intestinal hormones on obesity and pre-diabetes, two risk factors for type 2 diabetes and cardiovascular disease. They would mainly concentrate on two key areas:
1) Preventing or treating obesity, pre-diabetes and type 2 diabetes.
The research will help to better understand the role of incretins, including GLP-1(glucagon-like peptide 1) in the progression of obesity, pre-diabetes and type 2 diabetes. The findings could provide more insight into what biomarkers might be used to allow earlier intervention to prevent and/or treat obesity and/or pre-diabetes before type 2 diabetes develops.
2) Regulating weight, satiety and cardiovascular risk factors.
The investigation will look beyond the direct effects of incretins, including GLP-1, and into areas such as weight control, satiety and the effects on cardiovascular risk factors such as triglycerides and blood pressure.
Definitely a good news for all diabetes affected patients. Lets hope the study starts quickly and ends successfully.
Filed under Diabetes, Diabetes Drug, Prediabetes | Tags: American Diabetes Association, cardiovascular disease, Diabetes, diabetes research, health, hormones, Nova Nordisk, Obesity, pre-diabetes | Comment Below